Polycythemia medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 29: Line 29:
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Erythromelalgia
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Erythromelalgia
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Aspirin, 50 to 100 mg daily<br>Myelosuppressive agents
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Aspirin, 50 to 100 mg daily<br>Myelosuppressive agents
|-
|}
{{clear}}
'''Myelosuppressive Agents for the Treatment of Polycythemia Vera'''<ref name="pmid15152961">{{cite journal| author=Stuart BJ, Viera AJ| title=Polycythemia vera. | journal=Am Fam Physician | year= 2004 | volume= 69 | issue= 9 | pages= 2139-44 | pmid=15152961 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15152961  }} </ref>
{| style="border: 2px solid #4479BA; align="left"
! style="width: 200px; background: #4479BA;" | {{fontcolor|#FFF|Agent}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|Class}}
! style="width: 400px; background: #4479BA;" | {{fontcolor|#FFF|Common side effects}}
! style="width: 500px; background: #4479BA;" | {{fontcolor|#FFF|Uncommon side effects}}
! style="width: 600px; background: #4479BA;" | {{fontcolor|#FFF|Percautions}}
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Hydroxyurea (Hydrea)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Antimetabolite
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Anemia, neutropenia, oral ulcers, skin ulcers, hyperpigmentation, nail changes
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Leg ulcers, nausea, diarrhea, fever, elevated liver function test results
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Renal disease
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Recombinant interferon alfa-2b (Intron A)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Myelosuppressive
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Influenza-like symptoms, fatigue, anorexia, weight loss, alopecia, headache, nausea, insomnia, body pain
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Confusion, depression, autoimmunity, hyperlipidemia
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Psychiatric disease, cardiovascular disease
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Radioactive phosphorus
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Radiopharmaceutica
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Anemia, thrombocytopenia, leukopenia, Leukemia may develop after treatment
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Diarrhea, fever, nausea, emesis
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | —
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Busulfan (Myleran)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Alkylating agent
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Pancytopenia, hyperpigmentation, ovarian suppression
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Pulmonary fibrosis, leukemia, seizure, hepatic veno-occlusion
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Seizure disorder
|-
|-
|}
|}

Revision as of 16:27, 16 December 2020

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia medical therapy

CDC on Polycythemia medical therapy

Polycythemia medical therapy in the news

Blogs on Polycythemia medical therapy

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

  • Phlebotomy: the backbone of therapy, treatment with phlebotomy alone associated with a longer median survival compared to the use of chlorambucil or radioactive phosphorous based on a trial conducted by PV study group. Repeated phlebotomies help in cytoreduction and reduce hyper-viscosity in addition to induce a state of iron-deficiency which can help retard red-cell proliferation. Weekly sessions are conducted, by remove 500ml of blood until a target hematocrit of under 45% is obtained. This can lower rates of cardiovascular deaths and major thrombotic episodes in patients kept under this threshold based on a trial conducted in Italy. For secondary polycythemias, phlebotomy is usually reserved for the following conditions:
    • Chronic lung diseases
    • Cyanotic heart diseases
    • Post-renal transplant patients with hypertension and erythrocytosis, not responding to optimal doses of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARB) [1] [2]
  • Medicines that may be used include:[3]
    • Hydroxyurea: it used to reduce red blood cells counts and other blood cells if high. It also used to prevent thrombosis in patients >60 years of age with chronic PV.
    • Interferon: reduce blood cell counts.PegIFN can be used to reduce established splenomegaly but not usually to normal size.
    • Anagrelide: used to treat thrombocytosis.
    • Ruxolitinib (JAK1/2 inhibitor): proved to be effective in PPMF and chronic-phase PV; provided durable symptom relief, blood count control, and reduction in splenomegaly; and was superior to hydroxyurea.
    • Aspirin: used to prevent thrombosis.
  • Ultraviolet-B light therapy: reduce the itchiness.


Sumptomatic Treatment in Polycythemia Vera[4]

Symptoms Treatment
Pruritus H1 and H2 blocking antihistamines (diphenhydramine [Benadryl], cyproheptadine [Periactin], hydroxyzine [Atarax, Vistaril], fexofenadine [Allegra], terfenadine [Seldane])
Paroxetine (Paxil)
Oatmeal or starch baths (in lukewarm water)
Recombinant interferon alfa-2b (intronA)
Erythromelalgia Aspirin, 50 to 100 mg daily
Myelosuppressive agents


Myelosuppressive Agents for the Treatment of Polycythemia Vera[4]

Agent Class Common side effects Uncommon side effects Percautions
Hydroxyurea (Hydrea) Antimetabolite Anemia, neutropenia, oral ulcers, skin ulcers, hyperpigmentation, nail changes Leg ulcers, nausea, diarrhea, fever, elevated liver function test results Renal disease
Recombinant interferon alfa-2b (Intron A) Myelosuppressive Influenza-like symptoms, fatigue, anorexia, weight loss, alopecia, headache, nausea, insomnia, body pain Confusion, depression, autoimmunity, hyperlipidemia Psychiatric disease, cardiovascular disease
Radioactive phosphorus Radiopharmaceutica Anemia, thrombocytopenia, leukopenia, Leukemia may develop after treatment Diarrhea, fever, nausea, emesis
Busulfan (Myleran) Alkylating agent Pancytopenia, hyperpigmentation, ovarian suppression Pulmonary fibrosis, leukemia, seizure, hepatic veno-occlusion Seizure disorder

References

  1. Assi TB, Baz E (2014). "Current applications of therapeutic phlebotomy". Blood Transfus. 12 Suppl 1: s75–83. doi:10.2450/2013.0299-12. PMC 3934278. PMID 24120605.
  2. "StatPearls". 2020. PMID 30252337.
  3. Spivak JL (2019). "How I treat polycythemia vera". Blood. 134 (4): 341–352. doi:10.1182/blood.2018834044. PMID 31151982.
  4. 4.0 4.1 Stuart BJ, Viera AJ (2004). "Polycythemia vera". Am Fam Physician. 69 (9): 2139–44. PMID 15152961.

Template:WH Template:WS